Présentation de l'entreprise
OnKure Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Within the healthcare sector, specifically the biotechnology industry, this operational focus implies a reliance on extensive research and development pipelines rather than immediate commercial product sales, which is characteristic of entities in the pre-revenue or early-stage commercial phase. The company's market capitalization stands at $54.56M, supported by a workforce of 45 employees, while reported annual revenue figures are not disclosed as N/A in the current financial reporting. These valuation and headcount metrics indicate a small-cap enterprise with a lean operational structure, suggesting that the company's current market value is driven primarily by the potential future value of its asset pipeline, such as its lead product candidate OKI-219, rather than established cash flows from commercial operations.
Santé financière
The company reports a net income of $-59,517,000 and an EBITDA of $-62,503,000 over the trailing twelve months, while revenue figures are listed as N/A. The significant gap between the reported net income and EBITDA figures, which differ by approximately $2,986,000, reveals a cost structure dominated by non-operating expenses or significant interest costs, although the specific breakdown of these non-operating items is not detailed in the provided data. Free cash flow stands at $-31,100,750, indicating that the company is currently consuming cash to fund its operations and development efforts rather than generating surplus liquidity for shareholders or debt repayment. All three reported margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure typical for clinical-stage biotechnology firms where revenue has not yet scaled sufficiently to cover the substantial fixed costs of research, development, and administrative overhead. On the liability side, the company holds $59.05M in cash against a relatively minimal debt obligation of $549,000, resulting in a debt-to-equity ratio of 0.98. Despite the positive cash balance, the presence of debt alongside negative earnings suggests a balance sheet that is leveraged relative to its equity base, relying heavily on its cash reserves to service obligations and fund operations. The current ratio is reported at 10.28, which indicates an exceptionally strong short-term liquidity position, as the company holds more than ten times the current assets necessary to cover its short-term liabilities. Return on equity is -74.4% and return on assets is -44.5%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than profits, a common characteristic in the biotech sector during the development phase but one that signals a lack of profitability at this stage of the company's lifecycle.
Évaluation de la valorisation
The trailing P/E ratio is listed as N/A due to the absence of earnings, while the forward P/E is calculated at -1.40. The discrepancy between these two metrics, particularly the negative forward P/E, implies that analysts or market models are pricing in future earnings expectations that have not yet materialized, yet the company's current lack of profitability prevents a standard trailing valuation multiple from being applied. The price-to-book ratio stands at 0.97, indicating that the market values the company at a slight discount to its book value, which may reflect the challenges associated with valuing intangible assets like drug pipelines in the absence of commercial revenue. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A, and the EV/EBITDA stands at 0.06; these figures suggest that traditional earnings-based valuation models are not applicable, and the company must be assessed based on its asset liquidity and potential for future product approval. The stock's 52-week high is $5.10 and the 52-week low is $1.70, meaning the current price sits within a wide trading range that reflects high volatility typical of small-cap biotechnology stocks. The beta is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market, but the wide spread between the high and low suggests significant price sensitivity to clinical trial results or market sentiment regarding the biotech sector.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the company's status as a clinical-stage entity that has not yet achieved consistent commercial sales or profitability. Consequently, it is not possible to determine whether earnings are growing faster or slower than revenue because neither metric exists in a historical commercial context for this specific company. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, instead reinvesting its substantial cash reserves into research and development activities to advance its pipeline of precision medicines. The overall growth and income profile for OnKure Therapeutics is characterized by a complete absence of current commercial growth or dividend income, with value entirely dependent on the successful translation of its lead product candidates into approved therapies.